MedTrace Logo

Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma

NCT05907772 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 522

Last updated 2023-06-18

No results posted yet for this study

Summary

This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.

Conditions

  • Cancer of Liver

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-27
Primary Completion
2022-10-25
Completion
2022-11-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05907772 on ClinicalTrials.gov